The hypothesis is that brief, cyclic activation of OSKM induces a rapid, TET‑mediated oxidation of 5‑methylcytosine to 5‑hydroxymethylcytosine at lineage‑specific enhancers, creating a protective hydroxymethylation layer that maintains enhancer accessibility and prevents the loss of epigenetic memory. This wave occurs within the first 3‑7 days of reprogramming, preceding any detectable decline in somatic identity markers, and therefore defines the therapeutic window for safe rejuvenation partial reprogramming evidence. When OSKM expression is prolonged, the demand for TET activity exceeds cellular capacity, leading to passive dilution of 5‑hmC, erosion of enhancer hydroxymethylation, and eventual enhancer silencing that accompanies dedifferentiation and tumorigenic risk sustained expression teratoma.

Three specific, testable predictions follow from this mechanism:

1. Early 5‑hmC enrichment predicts safety – In fibroblasts undergoing a single 4‑hour OSKM pulse, oxidative bisulfite sequencing will show a significant increase in 5‑hmC at promoters and enhancers of fibroblast‑specific genes (e.g., Col1a1, Fn1) by 6 hours, coinciding with retained expression of these genes enhancer carriers of epigenetic memory. If 5‑hmC does not rise at these sites, the protective window is absent.

2. TET inhibition shortens the window – Treatment with the selective TET inhibitor Bobcat339 during OSKM pulsing will block the 5‑hmC rise, cause premature loss of enhancer accessibility (measured by ATAC‑seq), and reduce fibroblast‑specific transcript levels even with the same short pulse duration. Consequently, extending the pulse to 8 hours will now trigger ectopic pluripotency marker expression (Nanog, Oct4) and increase teratoma incidence in vivo short‑term cyclic induction improves health.

3. TET2 overexpression extends the window – Adenoviral delivery of TET2 will amplify the 5‑hmC signal, allowing OSKM pulses up to 12 hours to retain fibroblast enhancer hydroxymethylation and gene expression without activating pluripotency networks. In aged mice, liver‑targeted TET2‑OSKM co‑delivery should yield greater reversal of epigenetic age clocks than OSKM alone, with no increase in tumor formation after months of cyclic treatment OSK‑only enables long‑term expression.

Experimental approach: Use a doxycycline‑inducible OSKM cassette in primary mouse embryonic fibroblasts. Collect cells at 0, 2, 4, 6, 8, 12, and 24 hours after doxycycline withdrawal (to mimic a pulse). Perform oxidative bisulfite sequencing (oxBS‑seq) for 5‑mC/5‑hmC, ATAC‑seq for chromatin openness, and RNA‑seq for lineage and pluripotency transcripts. Parallel cultures receive Bobcat339 (1 µM) or AAV‑TET2. In vivo, administer doxycycline‑inducible OSKM to aged mice with or without liver‑specific TET2 overexpression, assess epigenetic age (Horvath mouse clock), fibrosis markers, and monitor for teratoma formation over 6 months in vivo short cycle reverses methylation.

Falsifiability: If TET inhibition fails to alter 5‑hmC dynamics, enhancer accessibility, or identity preservation during short OSKM pulses, or if TET2 overexpression does not extend the safe pulse length, the proposed TET‑dependent protective wave is refuted. Conversely, confirmation of these outcomes would support the hypothesis that modulating TET activity defines the boundary between beneficial rejuvenation and hazardous dedifferentiation.